Sheridan Capital Partners (Sheridan) has made an investment in RS&A, an established medical device independent service provider (ISP).
Sheridan has invested alongside RSA’s founding team, which retains a meaningful ownership stake in the business and will remain active in the operations of the Company.
Founded in 1995 by Carl Hill and Kenneth Wolff, RSA has scaled from a regional service team to a well-established independent service provider, serving a blue-chip customer base within radiation therapy. RSA specialises in a wide range of support services needed to maintain radiotherapy equipment used in the treatment of cancer patients, most notably medical linear accelerators (LINACs).
